Rhythm Pharmaceuticals: A Hidden Growth Stock Soaring
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Source: Fool
- Significant Market Potential: Rhythm Pharmaceuticals has a market cap of $6.8 billion, and despite its relatively small size, its stock has outperformed both Alphabet and Nvidia over the past 12 months, indicating strong market performance and investor confidence.
- Notable Sales Growth: The company's sole approved drug, Imcivree, achieved sales of $194 million in 2025, reflecting a year-over-year increase of approximately 50%, highlighting the growing market demand in the rare genetic obesity treatment sector.
- Promising Clinical Trials: Rhythm expects to advance its oral MC4R agonist, bivamelagon, into Phase 3 clinical testing in 2026, alongside another candidate, RM-718, in Phase 1 testing, showcasing the diversity of its pipeline and potential for market expansion.
- FDA Approval Catalyst: The anticipated FDA approval for Imcivree in treating acquired hypothalamic obesity on March 20, 2026, could potentially benefit over 36,000 patients across the U.S., Europe, and Japan, significantly enhancing the company's market outlook and profitability prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 114.430
Low
123.00
Averages
140.62
High
167.00
Current: 114.430
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rhythm Pharmaceuticals Publishes Setmelanotide Trial Results for Hypothalamic Obesity
- Clinical Trial Results: Rhythm Pharmaceuticals' TRANSCEND trial results indicate that patients treated with Setmelanotide achieved a 19.8% reduction in BMI over 52 weeks, significantly outperforming the placebo group's 3.3% increase, demonstrating the drug's efficacy in treating acquired hypothalamic obesity.
- Positive Patient Response: Among treated patients, 80% achieved at least a 5% reduction in BMI, alongside clinically meaningful improvements in hunger, highlighting Setmelanotide's potential to enhance the quality of life for patients.
- FDA Approval Milestone: In March 2026, the U.S. FDA approved Setmelanotide as the first therapy for acquired hypothalamic obesity, marking a significant breakthrough in treatment options and addressing a critical need for patients.
- Stable Market Reaction: RYTM stock has traded between $74.50 and $122.20 over the past year, closing at $114.43, reflecting market confidence in the company's prospects despite slight recent fluctuations.
See More
Rhythm Pharmaceuticals Publishes TRANSCEND Trial Results
- Clinical Trial Results: Rhythm Pharmaceuticals' TRANSCEND trial demonstrated that patients treated with setmelanotide achieved an average 16.5% reduction in body mass index (BMI) over 52 weeks, significantly outperforming the placebo group's 3.3% change, indicating the drug's efficacy in treating acquired hypothalamic obesity.
- Positive Patient Response: Among 120 participants, 80% experienced a BMI reduction of over 5% post-treatment, which not only addresses the urgent need for effective therapies but also positions Rhythm Pharmaceuticals favorably in the competitive landscape.
- Regulatory Approval Progress: In March 2026, the FDA approved setmelanotide as the first drug for acquired hypothalamic obesity, with the EU also recommending marketing authorization, highlighting the drug's potential in the global market.
- Future Development Strategy: Rhythm Pharmaceuticals plans to submit regulatory applications in Japan, aiming to bring this first-in-class therapy to patients worldwide, further solidifying its leadership in the rare neuroendocrine disease sector.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment
- Clinical Trial Progress: Rhythm Pharmaceuticals presented preliminary results from the Phase 2 trial of Setmelanotide for Prader-Willi syndrome at ENDO 2026, showing a 3.60% mean reduction in BMI among 18 patients over 52 weeks, laying a strong foundation for further drug development.
- Weight Management Efficacy: Participants exhibited a mean gain of 0.74 in lean mass and a mean loss of 4.19 in fat mass as measured by DEXA scans, indicating significant effects of Setmelanotide in weight control and body composition improvement, which may attract more patients to the drug.
- Symptom Improvement: Patients assessed by the Hyperphagia Questionnaire showed a decrease of 7 or more points in hyperphagia, while anxiety levels also decreased, suggesting that the drug not only aids in weight management but may also improve patients' mental health.
- Future Trial Plans: The company stated that the positive results from the Phase 2 trial will support the advancement of Setmelanotide into an upcoming Phase 3 trial, further validating its efficacy and safety in treating Prader-Willi syndrome, which could positively impact the company's future market performance.
See More
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment
- Clinical Trial Results: In a trial involving 17 patients with Prader-Willi syndrome (PWS), treatment with setmelanotide resulted in a mean BMI reduction of 3.06%, with 6 out of 10 adult patients achieving over 2.5% BMI reduction, indicating the therapy's effectiveness in weight management and potential improvement in patients' quality of life.
- Body Composition Improvement: Among 16 patients assessed via DEXA scans, setmelanotide led to a mean gain of 0.74% in lean mass and a mean loss of 4.19% in fat mass, demonstrating the drug's ability to facilitate weight loss while preserving muscle mass, thereby enhancing overall health outcomes for patients.
- Emotional and Behavioral Improvements: Of the 15 patients with baseline anxiety scores above 11, 10 achieved significant improvements in anxiety and emotional distress measures, suggesting the therapy's potential to alleviate psychological burdens for both patients and their caregivers.
- Future Development Plans: Following these positive results, Rhythm Pharmaceuticals intends to advance setmelanotide into Phase 3 trials for PWS, further validating its long-term efficacy and safety, reflecting the company's strategic commitment to addressing rare diseases.
See More
Rhythm Pharmaceuticals to Host Conference Call on Interim Phase 2 Results
- Interim Results Announcement: Rhythm Pharmaceuticals will host a conference call on June 13 to discuss interim six-month results from its Phase 2 trial for Prader-Willi syndrome, which is expected to attract attention from investors and healthcare professionals, potentially impacting the company's stock price.
- Leadership Participation: The call will feature insights from CEO David Meeker, M.D., and Dr. Jennifer Miller from the University of Florida, enhancing market confidence in the company's clinical progress and possibly fostering positive investor sentiment about future prospects.
- IMCIVREE Drug Information: Rhythm's lead asset, IMCIVREE, has received FDA approval for treating obesity related to genetic conditions, and this meeting is anticipated to clarify its market applications, potentially driving sales growth.
- Clinical Development Plans: The company is advancing clinical development for IMCIVREE in other rare diseases, showcasing its innovative capabilities in the biopharmaceutical sector, which may lay the groundwork for future product line expansions.
See More
Rhythm Pharmaceuticals Publishes Setmelanotide Trial Results for Hypothalamic Obesity
- Clinical Trial Results: Rhythm Pharmaceuticals' TRANSCEND trial results indicate that patients treated with Setmelanotide achieved a 19.8% reduction in BMI over 52 weeks, significantly outperforming the placebo group's 3.3% increase, demonstrating the drug's efficacy in treating acquired hypothalamic obesity.
- Positive Patient Response: Among treated patients, 80% achieved at least a 5% reduction in BMI, alongside clinically meaningful improvements in hunger, highlighting Setmelanotide's potential to enhance the quality of life for patients.
- FDA Approval Milestone: In March 2026, the U.S. FDA approved Setmelanotide as the first therapy for acquired hypothalamic obesity, marking a significant breakthrough in treatment options and addressing a critical need for patients.
- Stable Market Reaction: RYTM stock has traded between $74.50 and $122.20 over the past year, closing at $114.43, reflecting market confidence in the company's prospects despite slight recent fluctuations.
See More
Rhythm Pharmaceuticals Publishes TRANSCEND Trial Results
- Clinical Trial Results: Rhythm Pharmaceuticals' TRANSCEND trial demonstrated that patients treated with setmelanotide achieved an average 16.5% reduction in body mass index (BMI) over 52 weeks, significantly outperforming the placebo group's 3.3% change, indicating the drug's efficacy in treating acquired hypothalamic obesity.
- Positive Patient Response: Among 120 participants, 80% experienced a BMI reduction of over 5% post-treatment, which not only addresses the urgent need for effective therapies but also positions Rhythm Pharmaceuticals favorably in the competitive landscape.
- Regulatory Approval Progress: In March 2026, the FDA approved setmelanotide as the first drug for acquired hypothalamic obesity, with the EU also recommending marketing authorization, highlighting the drug's potential in the global market.
- Future Development Strategy: Rhythm Pharmaceuticals plans to submit regulatory applications in Japan, aiming to bring this first-in-class therapy to patients worldwide, further solidifying its leadership in the rare neuroendocrine disease sector.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment
- Clinical Trial Progress: Rhythm Pharmaceuticals presented preliminary results from the Phase 2 trial of Setmelanotide for Prader-Willi syndrome at ENDO 2026, showing a 3.60% mean reduction in BMI among 18 patients over 52 weeks, laying a strong foundation for further drug development.
- Weight Management Efficacy: Participants exhibited a mean gain of 0.74 in lean mass and a mean loss of 4.19 in fat mass as measured by DEXA scans, indicating significant effects of Setmelanotide in weight control and body composition improvement, which may attract more patients to the drug.
- Symptom Improvement: Patients assessed by the Hyperphagia Questionnaire showed a decrease of 7 or more points in hyperphagia, while anxiety levels also decreased, suggesting that the drug not only aids in weight management but may also improve patients' mental health.
- Future Trial Plans: The company stated that the positive results from the Phase 2 trial will support the advancement of Setmelanotide into an upcoming Phase 3 trial, further validating its efficacy and safety in treating Prader-Willi syndrome, which could positively impact the company's future market performance.
See More
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment
- Clinical Trial Results: In a trial involving 17 patients with Prader-Willi syndrome (PWS), treatment with setmelanotide resulted in a mean BMI reduction of 3.06%, with 6 out of 10 adult patients achieving over 2.5% BMI reduction, indicating the therapy's effectiveness in weight management and potential improvement in patients' quality of life.
- Body Composition Improvement: Among 16 patients assessed via DEXA scans, setmelanotide led to a mean gain of 0.74% in lean mass and a mean loss of 4.19% in fat mass, demonstrating the drug's ability to facilitate weight loss while preserving muscle mass, thereby enhancing overall health outcomes for patients.
- Emotional and Behavioral Improvements: Of the 15 patients with baseline anxiety scores above 11, 10 achieved significant improvements in anxiety and emotional distress measures, suggesting the therapy's potential to alleviate psychological burdens for both patients and their caregivers.
- Future Development Plans: Following these positive results, Rhythm Pharmaceuticals intends to advance setmelanotide into Phase 3 trials for PWS, further validating its long-term efficacy and safety, reflecting the company's strategic commitment to addressing rare diseases.
See More
Rhythm Pharmaceuticals to Host Conference Call on Interim Phase 2 Results
- Interim Results Announcement: Rhythm Pharmaceuticals will host a conference call on June 13 to discuss interim six-month results from its Phase 2 trial for Prader-Willi syndrome, which is expected to attract attention from investors and healthcare professionals, potentially impacting the company's stock price.
- Leadership Participation: The call will feature insights from CEO David Meeker, M.D., and Dr. Jennifer Miller from the University of Florida, enhancing market confidence in the company's clinical progress and possibly fostering positive investor sentiment about future prospects.
- IMCIVREE Drug Information: Rhythm's lead asset, IMCIVREE, has received FDA approval for treating obesity related to genetic conditions, and this meeting is anticipated to clarify its market applications, potentially driving sales growth.
- Clinical Development Plans: The company is advancing clinical development for IMCIVREE in other rare diseases, showcasing its innovative capabilities in the biopharmaceutical sector, which may lay the groundwork for future product line expansions.
See More
